Study finds experimental coagulant risk for heart patients

08/30/2011 | Reuters

The addition of experimental anti-clotting drug darexaban to anti-platelet therapy resulted in a two- to fourfold increase in bleeding among patients with acute coronary syndrome, a Phase II study found. The oral factor Xa inhibitor is undergoing a test for stroke prevention in subjects with atrial fibrillation and previously showed promise in reducing blood-clot risk after orthopedic surgery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ